SCHEMBL9494

SCHEMBL9494

c1ccc(Cc2nnco2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ NPC1 O15118 4/20 0.47
▸ HPGD P15428 2/20 0.47
▸ TSHR P16473 2/20 0.47
▸ GPR55 Q9Y2T6 1/20 0.47
▸ NOTUM Q6P988 1/20 0.45
▸ CALM1 P0DP23 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ PTK2 Q05397 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ DAGLA Q9Y4D2 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ ELANE P08246 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ EGFR P00533 1/20 0.38
▸ ERBB2 P04626 1/20 0.38
▸ S1PR1 P21453 1/20 0.38
▸ MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29291074 0.87 ALDH1A1 (0.39) RAB9ASMN1; SMN2NPC1HPGDTSHR
Ethoxycarbonyl Group SCHEMBL28264125 0.82 SMN1; SMN2 (0.35) RAB9ASMN1; SMN2NPC1HPGDTSHR
SCHEMBL18462192 0.82 CES1 (0.50) RAB9ASMN1; SMN2NPC1HPGDNOTUM
SCHEMBL23997326 0.80 RAB9A (0.42) RAB9ASMN1; SMN2NPC1HPGDTSHR
SCHEMBL30578709 0.80 KMT2A (0.44) RAB9ASMN1; SMN2NPC1HPGDTSHR
SCHEMBL23997494 0.80 HRH3 (0.38) —
SCHEMBL17994177 0.80 NOTUM (0.48) RAB9ASMN1; SMN2NPC1HPGDTSHR
SCHEMBL1172173 0.77 TSHR (0.54) RAB9ASMN1; SMN2NPC1TSHRNOTUM
SCHEMBL25281776 0.75 MAPK1 (0.42) SMN1; SMN2TSHRALDH1A1L3MBTL1MEN1
SCHEMBL12419308 0.75 MTNR1A (0.32) NOTUMPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563057-B Sulfonamide compound or salt thereof 大鹏药品工业株式会社 2022-06-24 — — CN disclosed
US-11034685-B2 Aminopyridine derivatives as TAM family kinase inhibitors SIGNALCHEM LIFESCIENCES CORPORATION (CA) 2021-06-15 — — US disclosed
US-11034686-B2 Aminopyridine derivatives as TAM family kinase inhibitors SIGNALCHEM LIFESCIENCES CORPORATION (CA) 2021-06-15 — — US disclosed
US-20200299287-A1 AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORPORATION (CA) 2020-09-24 — — US disclosed
US-20200299288-A1 AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORPORATION (CA) 2020-09-24 — — US disclosed
US-10723725-B2 Aminopyridine derivatives as TAM family kinase inhibitors SIGNALCHEM LIFESCIENCES CORPORATION (CA) 2020-07-28 — — US disclosed
US-20190152965-A1 AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORPORATION (CA) 2019-05-23 — — US disclosed
US-10233176-B2 Aminopyridine derivatives as TAM family kinase inhibitors SIGNALCHEM LIFESCIENCES CORPORATION (CA) 2019-03-19 — — US disclosed
US-10000456-B2 Polycyclic compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2018-06-19 — — US disclosed
US-20180028660-A1 DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST JANSSEN PHARMACEUTICA NV (BE) 2018-02-01 — — US disclosed
US-8664220-B2 Polycyclic compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2014-03-04 — — US disclosed
US-20130072490-A1 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS INC. (US) 2013-03-21 — — US disclosed
CN-102770415-A Polycyclic compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS INC 2012-11-07 — — CN disclosed
EP-2483251-A2 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS Amira Pharmaceuticals, Inc. (US) 2012-08-08 — — EP disclosed
EP-2483269-A2 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS Amira Pharmaceuticals, Inc. (US) 2012-08-08 — — EP disclosed
WO-2011041461-A2 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-07 — — WO disclosed
WO-2011041462-A2 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-07 — — WO disclosed
US-20110082164-A1 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-07 — — US disclosed
CN-101014594-A Piperidine derivatives as renin inhibitors SPEEDEL EXPERIMENTA AG (CH) 2007-08-08 — — CN disclosed
CN-1143958-A (4,4-difluorobut-3-enylthio-)-substituted heterocyclic or carbocyclic ring compounds ZENECA LTD (GB) 1997-02-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299287-A1 AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS MAP3K6, MAP3K5, MERTK RAB9A 1359/4885SMN1; SMN2 4800/4885NPC1 4565/4885
US-10723725-B2 Aminopyridine derivatives as TAM family kinase inhibitors MAP3K6, MAP3K5, MERTK RAB9A 1359/4885SMN1; SMN2 4800/4885NPC1 4565/4885
US-11034685-B2 Aminopyridine derivatives as TAM family kinase inhibitors MAP3K6, MAP3K5, MERTK RAB9A 1359/4885SMN1; SMN2 4800/4885NPC1 4565/4885
US-11034686-B2 Aminopyridine derivatives as TAM family kinase inhibitors MAP3K6, MAP3K5, MERTK RAB9A 1359/4885SMN1; SMN2 4800/4885NPC1 4565/4885
US-20130072490-A1 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR4 RAB9A 2536/4885SMN1; SMN2 4422/4885NPC1 339/4885
US-10233176-B2 Aminopyridine derivatives as TAM family kinase inhibitors MAP3K6, MAP3K5, MERTK RAB9A 1359/4885SMN1; SMN2 4800/4885NPC1 4565/4885
US-20110082164-A1 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR4 RAB9A 2536/4885SMN1; SMN2 4422/4885NPC1 339/4885
US-20180028660-A1 DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST PPARG, PPARA, DGAT1 RAB9A 3123/4885SMN1; SMN2 4874/4885NPC1 342/4885
US-20200299288-A1 AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS MAP3K6, MAP3K5, MERTK RAB9A 1359/4885SMN1; SMN2 4800/4885NPC1 4565/4885
US-20190152965-A1 AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS MAP3K6, MAP3K5, MERTK RAB9A 1359/4885SMN1; SMN2 4800/4885NPC1 4565/4885
US-10000456-B2 Polycyclic compounds as lysophosphatidic acid receptor antagonists LPAR1, LPAR2, LPAR4 RAB9A 2536/4885SMN1; SMN2 4422/4885NPC1 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback